Trial · NCT03660397
Adrenal Artery Ablation for Uncontrolled Hypertension
NCT03660397, Phase 3, Unknown, Third Military Medical University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Adrenal Artery Ablation for Uncontrolled Hypertension. Trials, record NCT03660397. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03660397
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Adrenal Artery Ablation for Uncontrolled Hypertension
- NCT number
- NCT03660397
- Status
- Unknown
- Phases
- Phase 3
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Third Military Medical University
- Conditions
- Uncontrolled Hypertension
- Interventions
- Selective endovascular chemical ablation of adrenal gland, Traditional triple antihypertensive treatment
- First posted
- 2018-09-06
- Last updated
- 2018-09-06
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change of 24-h average systolic blood pressure measured at baseline and the end of the trial | 24 weeks | Difference in the change of 24-h average systolic blood pressure between the intervention and control group is to be analysed. |
| Secondary | Change of 24-h average systolic blood pressure compared with the baseline | 24 weeks | Change of 24-h average systolic blood pressure compared with the baseline at the end of the study (24 weeks) in the intervention group. |
| Secondary | Change of anti-hypertensive regimen measured at baseline and the end of the trial | 24 weeks | Difference in the change of anti-hypertensive regimen between the intervention and control group is to be analysed. |
| Secondary | Change of 24-h average diastolic blood pressure, daytime mean systolic blood pressure, daytime mean diastolic blood pressure, and nighttime average systolic and diastolic blood pressure measured at baseline and the end of the trial | 24 weeks | Difference in the change of 24-h average diastolic blood pressure, daytime mean systolic blood pressure, daytime mean diastolic blood pressure, and nighttime average systolic and diastolic blood pressure between the intervention and control group is to be analysed. |
| Secondary | Change of home systolic and diastolic pressure measured at baseline and the end of the trial | 24 weeks | Difference in the change of home systolic and diastolic pressure between the intervention and control group is to be analysed. |
| Secondary | Change of office systolic and diastolic pressure measured at baseline and the end of the trial | 24 weeks | Difference in the change of office systolic and diastolic pressure between the intervention and control group is to be analysed. |
| Secondary | Change of blood electrolytes measured at baseline and the end of the trial | 24 weeks | Difference in the change of blood electrolytes between the intervention and control group is to be analysed. |
| Secondary | Change of plasma and urine adrenal hormones measured at baseline and the end of the trial | 24 weeks | Difference in the change of plasma and urine adrenal hormones between the intervention and control group is to be analysed. |
| Secondary | Change of plasma renin measured at baseline and the end of the trial | 24 weeks | Difference in the change of plasma renin between the intervention and control group is to be analysed. |
| Secondary | Change of liver enzymes measured at baseline and the end of the trial | 24 weeks | Difference in the change of liver enzymes (ALT, AST in IU/L) between the intervention and control group is to be analysed. |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03660397
GET https://conductscience.org/api/trials/v1/NCT03660397/registered